YRDC Mediates the Resistance of Lenvatinib in Hepatocarcinoma Cells via Modulating the Translation of KRAS

• Main Authors: Jun Guo (Author), Peng Zhu (Author), Zhi Ye (Author), Mengke Wang (Author), Haijun Yang (Author), Shiqiong Huang (Author), Yan Shu (Author), Wei Zhang (Author), Honghao Zhou (Author), Qing Li (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Lenvatinib is the latest and promising agent that has demonstrated a significant improvement of progression-free survival in advanced hepatocellular carcinoma (HCC). However, resistance emerges soon after initial treatment, limiting the clinical benefits of lenvatinib. Therefore, understanding the m...